# China NMPA Inspection - Jiangxi Kangding Biotechnology Co., Ltd. - December 07, 2020

Source: https://www.globalkeysolutions.net/records/china_inspection/jiangxi-kangding-biotechnology-co-ltd/955c81e6-f255-4b47-9192-1a41086efb60/
Source feed: China

> China NMPA unannounced inspection for Jiangxi Kangding Biotechnology Co., Ltd. published December 07, 2020. The Jiangxi Provincial Drug Administration, operating within the broader regulatory framework of the National Medical Products Administration (NMPA) i

---

## Details

- Record Type: CHINA_INSPECTION
- Title: Announcement No. 44 of 2020 from the Jiangxi Provincial Drug Administration Regarding the Supervision and Inspection of Cosmetic Manufacturers
- Company Name: Jiangxi Kangding Biotechnology Co., Ltd.
- Publication Date: 2020-12-07
- Product Type: cosmetics
- Summary: The Jiangxi Provincial Drug Administration, operating within the broader regulatory framework of the National Medical Products Administration (NMPA) in China, conducted follow-up supervision and inspections of 14 cosmetics manufacturers in October 2020. This initiative aimed to reinforce enterprises' primary responsibility for quality and safety in cosmetics production, with findings announced on December 7, 2020.Inspections, typically spanning two days for each company, revealed a range of deficiencies across the audited facilities. Common issues included multiple serious and general (or minor) deficiencies in operational practices and quality systems. For instance, Jiangxi Kangding Biotechnology Co., Ltd. was cited for 4 serious and 6 general deficiencies, while Jiangxi Haichuan Pharmaceutical Co., Ltd. had 4 serious and 10 minor deficiencies, alongside non-standardized or incomplete registration materials for some products.Regulatory actions varied based on the severity of findings. Most companies, including Jiangxi Zhenshiming Pharmaceutical Co., Ltd. and Shuangfeiren Pharmaceutical Co., Ltd., were required to rectify identified deficiencies and submit a comprehensive rectification report to the bureau within 30 days. More stringent measures were taken against companies with significant non-compliance: Jiangxi Baiquan Industrial Co., Ltd., facing 6 serious and 9 minor deficiencies and failing to meet requirements, voluntarily applied for deregistration. Ji'an Yumeili Health Industry Co., Ltd., with 5 serious and 9 minor defects, was mandated to suspend production for rectification, with resumption contingent upon official confirmation from the regulatory authority. These inspections underscore a commitment to maintaining stringent quality standards in the cosmetics industry.

Company: https://www.globalkeysolutions.net/companies/jiangxi-kangding-biotechnology-co-ltd/d7564266-4394-4eb7-bb89-dc15cb7d8d88/